X

Trial Profile

A Phase 3 registrational trial of APL-2 in the patients cold agglutinin disease (CAD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegcetacoplan (Primary)
Indications Autoimmune haemolytic anaemia
Focus Registrational; Therapeutic Use

Most Recent Events

04 May 2022 According to an Apellis Pharmaceuticals media release, this trial is anticipated to begin in second quarter 2022.
27 Oct 2020 According to an Apellis Pharmaceuticals, Sobi media release, the companies plan to jointly advance the clinical development of systemic pegcetacoplan including this registrational study in cold agglutinin disease (CAD) which is expected to start in 2021.
19 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com